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Introduction
Drug formularies are a ubiquitous,
heterogeneous yet often contentious fea-
ture of both US and international drug
policy [1–6]. Formularies represent the
fundamental approach embodied in the
World Health Organization (WHO) Mod-
el Formulary 2004 and various countries’
essential medicines lists [1]. In addition,
WHO encourages each hospital to estab-
lish a drug and therapeutics committee to
oversee selection of drugs and to set
policies for that institution’s local formu-
lary [7]. Formularies and committees that
oversee them are present in some form in
virtually every US hospital and outpatient
drug plan and are highly visible compo-
nents of public drug benefits in many
countries. Thus decisions made by these
committees directly or indirectly impact
every prescriber, pharmacist, and patient
[8–11].
While some clinicians criticize formu-
laries for limiting clinical autonomy, others
have argued that formularies have strayed
from their original mission—to identify
and designate drugs of choice to guide
more rational prescribing—claiming in-
stead they have become overly focused on
cost containment and created needless
hurdles and complexities for physicians
and patients [10,12,13]. Nonetheless, for-
mularies can unquestionably exert a pow-
erful influence on prescribing decisions
and medication utilization [14–19]. At
their best, as vehicles and venues for
identifying, weighing, and designating best
evidence, formularies can assess, teach,
and guide prescribing toward the most
appropriate and evidence-based choices,
helping to direct use toward the most
efficacious, safest, and cost-effective ther-
apies, while serving as a firewall to protect
against prescribing overly driven by mar-
keting claims [11–13,16–21]. Through the
decision-making activities of the formulary
process, knowledge and leverage may be
applied to enhance prescribing practices
and patient outcomes in ways that go
beyond initial regulatory approval and
individual prescribers’ ability to weigh
the role and value of new medications
(Figure 1).
Tool Development
As members and chairs of multiple US
formulary committees, we observed that
the depth and quality of debate, discus-
sion, and deliberation around decisions to
add a product to the formulary varied
tremendously from drug to drug, com-
mittee to committee, and meeting to
meeting. Lacking a more rigorous frame-
work for evaluating requested drugs, and
faced with packed meeting agendas that
never seemed to permit sufficient time to
thoroughly explore decision pros and
cons, monitoring requirements, and opti-
mal usage for proposed new drugs, we
observed that discussions were often
subjective, unsystematic, and incomplete
[13].
As part of a project sponsored by the US
Attorney General Consumer and Prescrib-
er Education Grant Program (funded by
the Neurontin settlement [22]), we had the
opportunity to bring together formulary
committeechairs and participants from two
public teaching hospitals and a university-
based school of pharmacy. Our initiative,
entitled the Formulary Leveraged Im-
proved Prescribing (FLIP) Project was
continued through the work of a US
Agency for Healthcare Research and
Quality–funded Center for Education and
Research in Therapeutics [23].
On the basis of our earlier research [13]
and more recent survey data from the
The Policy Forum allows health policy makers
around the world to discuss challenges and
opportunities for improving health care in their
societies.
Citation: Schiff GD, Galanter WL, Duhig J, Koronkowski MJ, Lodolce AE, et al. (2012) A Prescription for
Improving Drug Formulary Decision Making. PLoS Med 9(5): e1001220. doi:10.1371/journal.pmed.1001220
Published May 22, 2012
Copyright:  2012 Schiff et al. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: This work originated from the Formulary Leveraged Improved Prescribing (FLIP) project, which was
funded by the Attorney General Consumer and Prescriber Education Grant Program, and was supported by the
Agency for Healthcare Research and Quality grant U18HS016973 funding the UIC Center for Education and
Research on Therapeutics (CERT) program. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: WG received grant funding from Abbott Labs- 2% FTE this year, Consulting with
Walgreens (member of P&T Committee, ,$5,000). JD had a summer student internship with Abbott
Laboratories in Regulatory Affairs 2009–2010 7 k (2009) 8 k (2010). SW consulted for Abbott, Genentech,
Primus. MK is a Consultant Pharmacist, Pharmacy and Therapeutics Committee, Catalyst Health Solutions, Inc,
Rockville, MD. DT received unrestricted grant funding for research from Medco Health Solutions. BL consulted
in last 3 years: Abbott (drug name confusion), Transcept. Stock ownership: Pharm I.R., Inc. (my own company,
specializing in preventing and detecting drug name confusion errors). Expert witness testimony: Hernandez v.
Schering (for Hernandez), Mason v. General Electric Company, et al. (for Mason). Grants received: Abbott
(readability of MedGuides), Novartis (development of pharmacoepidemiologic methods), Ortho McNeil (safety
of warfarin post orthopedic surgery), AHRQ (Tools for Optimizing Prescribing). Patents received: BLL Consulting,
Inc. (related to preventing drug name confusions) Other: Board of Directors (unpaid) for Med-Errs, Inc. (drug
name confusion).
* E-mail: gschiff@partners.org
Provenance: Not commissioned; externally peer reviewed.
PLoS Medicine | www.plosmedicine.org 1 May 2012 | Volume 9 | Issue 5 | e1001220Institute for Safe Medication Practices
(ISMP) [24,25], we concluded that there
was a need to overcome various miscon-
ceptions about formularies. We saw an
opportunity to redirect formulary commit-
tee discussions away from less pertinent
issues (often reflecting differing general
assumptions and personal biases about the
fundamental purpose and role of formular-
ies) and toward more deliberative evalua-
tionof the evidencerelatedto theparticular
drugs and indications under review.
To address this need, we developed and
refined structured criteria to help direct
this critical evaluative process. We devel-
oped a checklist on the basis of the
experiences of the two formulary commit-
tee chairs (GDS, WLG) along with our
FLIP team members, which included two
general internists (pharmacy and thera-
peutics [P&T] Chairs), five pharmacists, a
former pharmaceutical sales representa-
tive, two pharmacoeconomists, and a
pharmacy communication expert. We
began by compiling a list of frequent
questions and issues arising in delibera-
tions of the two P&T Committees. The list
was then grouped into six domains and
iteratively refined by evaluating its com-
prehensibility, usefulness, completeness,
and applicability to formulary committee
meetings over the course of the 2-year
project. Additional input (and eventual
incorporation of selected portions of the
checklist) was obtained from the Univer-
sity of Illinois at Chicago (UIC) Drug
Information Group and the Academy of
Summary Points
N Drug formularies are widely used by hospitals, health systems, and private and
national drug insurance plans. Although considerable attention has been
devoted to their role in cost containment, formularies’ role in guiding rational
drug use remains underdeveloped and could be enhanced by a more
standardized critical evaluation of drugs proposed for formulary placement.
N We developed a tool based on a project at two US public academic hospitals
consisting of a six-domain checklist of questions for evaluating drugs requested
for addition.
N The tool poses 48 questions related to: evidence of need, efficacy, medication
safety, misuse potential, cost issues, and decision-making process.
N The checklist can facilitate more standardized and critical scrutiny of the
evidence and therapeutic alternatives. It can educate new committee members,
guide discussions of drugs proposed for formulary addition, and be used to
evaluate the quality of committee decision making.
N Limitations include its generalizability to all types of formulary committees and
settings, and lack of time and data for committees to fully address all checklist
questions.
Figure 1. Leveraging formularies for improved prescribing. Formularies are poised to enhance the quality of drug prescribing decision
making beyond that of individual practitioners. By encoding the collective expertise and judgment of a group of physicians and pharmacists who
have resources and experience to weigh evidence in context, formularies work in ten ways to help optimize prescribing. In addition to supporting the
decision making of individual clinicians, the formulary committee oversees the safe and effective use of drugs in institutions by providing guidance
and engaging in ongoing drug utilization review.
doi:10.1371/journal.pmed.1001220.g001
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with extensive experience preparing drug
monographs used for formulary commit-
tee decision making.
Formulary Drug Application
Evaluation Tool
The FLIP formulary drug application
evaluation tool poses a series of questions
that provide a framework for formulary
decision making (Box 1). These questions
are designed to assist formulary committee
members in evaluating claims made about
drugs being considered for addition to the
formulary and, if added, to assist in
deciding what restrictions or special mon-
itoring precautions should be put in place.
Emphasis centers on the quality of the
available evidence and on comparisons to
therapeutic alternatives. The ultimate
objective of the tool is to help committee
members critically evaluate the role for a
given drug in significantly improving
patient outcomes related to specific indi-
cation(s).
The tool is organized around the
following six broad questions: (A) Evidence
of need: Is there compelling evidence of a
need to add this drug to our formulary? (B)
Efficacy: What is the strength and quality
of evidence to support claims for this drug?
(C) Safety: What safety issues need to be
considered? (D) Misuse impact potential: If
placed on the formulary, what is the
potential for misuse or overuse? (E) Cost
Issues: Can we justify the cost of this drug?
(F) Decision-making information, calcula-
tions, timing and process: What is the
quality and completeness of evidence, and
deliberations of committee?
Effective Use of the FLIP Tool
To most effectively use this tool, a
number of caveats should be kept in mind.
First, given the rich diversity of formularies
and formulary committees, it would be
difficult to standardize a one-size-fits-all
tool—one equally applicable to all nation-
al and local, inpatient and outpatient
settings, public sector and private sector,
more restrictive and less controlled formu-
lary-based drug management environ-
ments and plans. Second, it is unrealistic
to expect that every question would be
addressed for every drug at every meeting,
certainly during the limited discussion
time typically available at formulary com-
mittee meetings. Thus, we present a
comprehensive list of questions that may
be more or less applicable depending on
the setting and drug. To save time during
the committee meetings, we anticipate that
the investigation of many of the checklist
questions might be done before rather
than during the meeting perhaps by a
clinical pharmacist preparing the drug
monograph.
Formulary committees often have lim-
ited time to make decisions, but an even
larger constraint is the paucity of evidence,
or at least high quality evidence, to answer
with confidence many of the questions the
checklist poses. This limitation is particu-
larly true for comparative effectiveness
assessments, a shortcoming that has re-
cently been prominently spotlighted but is
one that has long challenged thoughtful
formulary decision makers [26,27]. While
acknowledging this limitation in applying
the tool, we also view it as a strength, in
that the unanswerable questions can serve
to highlight evidence gaps and force the
committee to prioritize the key questions
for drugs being considered, underscoring
the need to proceed with caution when
crucial evidence is lacking.
With these caveats in mind, we suggest
the FLIP formulary drug evaluation tool
could be used in a number of ways,
depending on the type and scope of the
formulary committee as well as the time
and resources available. In many settings
there is an individual (e.g., a clinical
pharmacist) or group charged with pre-
paring a dossier of material for the
committee prior to the meeting to consider
a drug. The FLIP tool could be used to
structure this dossier, organizing the
material by topic and identifying gaps in
the evidence and unanswered questions.
Alternatively, the tool could be used to
organize and guide discussion during the
committee meeting. It could also be used
to educate new members of the committee
about the kinds of questions that need to
be raised when evaluating drugs for
formulary placement. Finally it could be
used for quality assessment and improve-
ment of the formulary committee process-
es itself, for example by recording or
reviewing formulary meetings and then
using the tool to determine how many of
the key questions were raised, how well
they were addressed, to examine how
effectively the formulary processes fulfilled
its role in overseeing critical, evidence-
based drug policies.
Discussion
In a recent review of the international
literature of the formulary decision-mak-
ing process at the hospital level, Ouachi et
al. concluded that there is a lack of
standardized procedures or methods for
decision making [5]. Given this gap and
the important role of the local and
national formularies in promoting rational
prescribing and aiding prescribers, institu-
tions, and insurers in evaluating drugs,
particularly new drugs, there is a need to
explicitly and systematically pose critical
questions that often fail to be asked or
addressed in claims for new drugs [9,13].
The tool frames questions in such a way
as to look for evidence of benefit and safety
before placing drugs on the formulary,
shifting the burden of proof onto those
who would advocate placing a drug on the
formulary, rather than the default assump-
tion that, unless there is a reason to the
contrary, all licensed drugs should be
included. This assumption embodies the
precepts of essential medicines as well
principles of conservative and cost-effec-
tive prescribing [28,29]. The questions
based on these principles assume that,
lacking evidence of superior safety, effica-
cy, or other comparative benefit, we ought
not to be exposing patients or promoting
and paying for expensive new drugs whose
risks are poorly understood [19,29].
Some might object to this shifting of the
burden of proof onto proponents of adding
drugs, arguing that it represents a bias
against newer drugs and their manufac-
turers. However, it seems appropriate to
shift this responsibility to those who
develop and market new drugs because
they are ethically and legally charged with
producing evidence of their product’s
safety and effectiveness. Pharmaceutical
manufacturers increasingly recognize this
responsibility to more rigorously address
these questions, and thus should welcome
more clearly defined and standardized
approaches.
We acknowledge that underutilization
of appropriate medications is also a
problem [26]. However, many underuti-
lized drugs are generic drugs that have
already found a place on the formulary.
Further, formularies are primarily respon-
sible for ensuring that needed drugs are
made available, not necessarily that their
use is promoted. Rather the tool is
designed to support a critical function of
the formulary—to serve as counter-
weight—balancing other forces that tend
to promote more liberal use of drugs (e.g.,
advertising, patient demands, time pres-
sure, inability of clinicians to have the time
and expertise to critically review claims).
The tool has not been systematically
evaluated to determine the impact of its
deployment on decision-making processes,
committee decisions, or clinical outcomes.
While some data exist demonstrating that
effective formularies can restrain costs
[30,31], there are few high quality studies
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A. Evidence of need
Is there a compelling need to add the drug to our formulary?
What is the prevalence and importance of the condition the drug is intended to treat? What is the relevance of this drug to our
population? Are there special subpopulations for which there may be a compelling need?
What are the demonstrated shortcomings of existing therapy? Is there evidence that this drug overcomes problems in safety,
efficacy, acceptability, or convenience that characterize existing therapy?
What role does this drug play in addressing this need? What are the US Food and Drug Administration (FDA), European
Medicines Agency (EMA), or other international agencies’ approved indications? What other claims for the drug are being made?
What other therapeutic approaches (including non-drug alternatives) might reasonably be pursued instead?
Is the drug needed for all the venues/settings for which it is being requested (e.g., for both inpatient and outpatient formulary use)?
B. Efficacy
What is the evidence to support the claims for this drug?
What is the quality and strength of the evidence supporting the efficacy claims? How well designed are these studies?
Are the claims (both on- and off-label) being made for this drug supported by the data presented?
How relevant is the population in the published studies to our population and patients in whom it is likely to be used? Were
patients like those we treat included in the clinical trials used to gain FDA, EMA, or other governmental regulatory approval, and
will the drug’s use likely be similar to patients where benefit is proven?
To what extent are the benefits based on surrogate measures (i.e., hemoglobin A1c, low-density lipoprotein [LDL], serum sodium)
rather than clinically relevant outcomes (e.g., mortality, quality of life, strokes)?
Does the published (or unpublished) literature contain conflicting evidence about efficacy? Is there suggestion of selective
publication, or selective sharing of only more favorable studies by those advocating formulary addition.
What is the ‘‘marginal efficacy’’—efficacy above and beyond other therapeutic alternatives?
Do the efficacy studies use proprietary or manufacturer-developed scales that may bias the findings to give favorable results (e.g.,
specialized, manufacturer-developed quality of life instruments targeted to be responsive to the effects of a particular drug)?
C. Safety
What safety issues need to be considered?
Is there a potential for look-alike, sound-alike name errors raised by or reported for this drug?
Are there safety issues surrounding the administration or preparation requirements?
What is the adequacy of the experience with the drug? What are the number and types of patients studied? How long has the drug
been used to assure there is a demonstrated safety track record (since many adverse effects only appear after 5–10 years of use)?
Are there suggestions of early warning signals (either in the literature, unpublished studies or reports, or theoretical concerns based
on class effects) of potential safety concerns (e.g., reports of hepatotoxicity, nephrotoxicity, or drug–drug interactions, QT
prolongation) that may be a red flag, cautioning against moving too quickly to approve the drug?
What patient monitoring or other special precautions (e.g., pregnant women, renal insufficiency, government-mandated risk
evaluation and mitigation strategies [REMS in US]), are needed or required to use the drug safely? How difficult will it be for
practitioners to comply with needed monitoring, and how likely are they to perform adequately?
How strong is the evidence of this drug’s safety compared to other drugs in its class, or other drugs for the same indication
currently on the market? What are the anticipated types of adverse events? How do the frequency, severity, preventability, and
ameliorability of these adverse events compare across alternative drugs for this indication?
D. Misuse impact potential
If placed on the formulary, what is the potential for misuse or overuse?
Is the drug subject to intensive marketing to either consumers or prescribers for questionable and/or off-label indications that may
lead to excessive or inappropriate use?
Is there evidence or worry that the drug will be subject to excessive or unrealistic patient demand and expectation? Are there
concerns that advertising, including direct-to-consumer in countries where this exists, will play a role in patient demand? Are
industry-funded patient advocacy groups aggressively lobbying for the drug, possibly creating pressures for premature or overuse?
Is there uncertainty or difficulty in accurately diagnosing the condition that is the indication for this drug, leading to potential
overuse or inappropriate use of the drug?
Are there concerns for widespread ‘‘off-label’’ usage?
Might the expansion of indications to new manufacturer-promoted syndromes play a role in this drug’s usage and potential for
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Is there experience (in our institution or published literature) with similar drugs and situations suggesting there may be overuse of
this agent?
Is there evidence that any of the active ingredients in the drug is addictive or habit forming?
E. Cost Implications
Can we justify the cost of this drug?
How much will it cost? Are there other relevant costs such as additional preparation, storage, administration, monitoring, or
other downstream costs beyond simple acquisition costs?
What is the cost and burden of additional monitoring requirements in safely using this drug?
What are the comparative costs of other alternatives (e.g., are generics available?)
Will a competitor/comparable drug soon become available generically?
If there is an added cost associated with using this drug, is there a significant clinical benefit that justifies the added expense?
What other pricing issues (rebate deals, market share or exclusivity requirements, some of which may not be transparent) may
impact purchasing this drug for our institution or patients? Will the price be raised later once we switch over to this drug (‘‘bait
and switch’’ pricing tactics)?
What are re-imbursement cost ramifications? What costs will be covered by private or public insurers versus what costs will be
borne by the institution or patients (as co- or full pay)?
What costs are involved in switching patients currently on another drug that we may be substituting this medication for
(additional visits, monitoring)?
Is pill-splitting a possibility for cost savings? Is it easy, safe, desirable?
How do the acquisition and above additional costs compare to evidence of cost savings (reduction in admissions, other
expenditures)?
F. Decision-making information, calculations, timing, and process
What is the strength and quality of evidence and information available to the Committee?
What is the source (i.e., from pharmaceutical sales representative versus independent review), completeness, timeliness, and
quality of the information the Committee has available to make a decision at this time?
Has an independent drug monograph review been prepared for the Committee (e.g., by a pharmacist or drug information
service)? If yes: Are the monograph and other information upon which decisions are being made adequate, or are there
unanswered questions (such as those raised in this document) that require additional information?
Are there reviews by other formulary or guideline committees or international drug bulletins whose judgments and decisions can
also help inform our discussion and decision?
Are there outstanding questions that may be answered by additional information (e.g., pending research trials) that may warrant
deferring a decision?
What is the status and quality of the review process and use at our institution?
Has the drug previously been reviewed by our formulary Committee? If yes what were the issues raised in prior review,
discussion, and decision? Was the process a fair and high quality group decision?
Have there been significant numbers of non-formulary requests for this drug at our institution or plan? If yes, what are utilization
and safety experiences and issues surrounding its non-formulary use? What are the pros and cons of keeping non-formulary status
for now?
Have the requisite subcommittees and key and knowledgeable specialists been consulted, how have they weighed in on the
decision?
Has there been undue influence or bias impacting the decision-making process? Have all conflicts of interest (financial, research
funding) been disclosed related to the requester, committee members, or involved with evaluating this drug’s formulary status
(e.g., desire to please a high income-generating clinician)?
What is desirability of approval now versus delaying approval pending additional information?
Which clinicians should be permitted to use this drug and in what clinical venue?
Should there be restrictions (e.g., clinical prior approval or other mechanisms) placed on this medication (based on indication,
safety, clinical, or cost outcomes)? If so, what should they be and how easily can they be operationalized and made to work
effectively minimizing administrative burdens?
Are there guidelines and/or electronic clinical decision support alerts that could help ensure safe and appropriate use of this
medication; how can they best be operationalized?
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ally improve clinical outcomes—studies
sorely needed given how many lives and
potentially adverse outcomes (either
caused or prevented) are at stake. Box 2
lists key questions that such studies,
particularly as they pertain to this tool,
will need to address. The Academy of
Managed Care Pharmacy has adopted an
earlier version of our checklist as an
appendix to version 3.0 of the AMCP
Format for Formulary Submissions—the
standard template that managed care
organizations use to request information
from manufacturers about products being
considered by formulary committees.
AMCP’s adoption of the tool suggests that
one influential US organization finds the
tool to be potentially useful for its
members, a limited but influential subset
of the target audience for this tool [32].
Our tool was found to be useful in two
US public hospital formularies. While not
representative of all settings and uses, one
hospital employs a formulary that is more
common in the US (overseeing only the
inpatient formulary), while the other
operates more on a ‘‘single payer’’ fixed
budget and oversees both inpatient and
outpatient drugs. Thus its applicability
appears to be reasonably broad. Here, we
offer the tool for a broader audience to
use and test. We hope that it will prove
useful in improving the quality of formu-
lary decision making and stimulating
debate related to critical questions that
need to be asked, highlighting essential
data needed to more safely prescribe
drugs. As a guide to posing critical
questions related to drugs being adopted,
it represents a starting point, for both
local formulary committees and national
policymakers to use in their evaluations
of new drugs for formulary inclusion as
well as to further evaluate, test, and
refine.
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Box 2. Evaluating and Sharpening the Formulary Decision-Making Tool: Questions to Further
Validate and Evaluate This Tool
Usability
Are the questions clear, reliably interpreted by members?
How easily can checklist be deployed by the Committee?
Is it feasible to address these questions (versus insufficient information, time)?
Relevance
Are these the high priority questions for the formulary committee (in general, for that particular committee)?
Are there important domains/questions overlooked?
Does it include unnecessary or less relevant questions?
Impacts
How does the tool impact decision-making process and outcomes?
In what ways does it help guide meeting discussions?
What is its impact on committee decisions, patient outcomes, costs?
Educational value and user satisfaction
Is it serving a useful educational purpose (orientating new members, others)?
Do committee members like it and find it helpful?
Broader (more indirect and speculative) impacts
Does the tool enhance committee transparency, credibility, status/recruitment of members?
Does it promote higher quality of monographs, materials prepared/distributed?
Will it lead to more standardized drug lists across settings?
Does it promote better support for formulary processes; lead to more regional/centralized formulary committees?
Impacts on industry—does it help create clearer expectations, raise bar for stimulating better information, better studies, or
even better drugs?
Adverse effects
Is use of the tool too costly, requiring excessive staff time to prepare/address?
Does it lead to keeping drugs off formulary that are later proven highly valuable (i.e., does it make the formulary overly
restrictive)?
Might its rigor and promotion of a stricter formulary antagonize clinicians, negatively impacting buy-in for formulary/decisions?
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